• Explore /
  • Poster
  • / Clinical study of VERU-111, an oral cytoskeletal disruptor, in metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.

Clinical study of VERU-111, an oral cytoskeletal disruptor, in metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.

Abstract Poster

Authors

null

Mark Christopher Markowski

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Mark Christopher Markowski , Mario A. Eisenberger , Ronald F. Tutrone , Christopher Michael Pieczonka , Robert H. Getzenberg , Domingo Rodriguez , K. Gary Barnette , Mitchell S. Steiner , Daniel R. Saltzstein , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03752099

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 131)

DOI

10.1200/JCO.2021.39.6_suppl.131

Abstract #

131

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Mark Christopher Markowski

First Author: Mark Christopher Markowski

First Author: Sumit Kumar Subudhi

First Author: David Johnson Einstein